Balanced news tone
News Sentiment
CRBP sentiment intelligence
Corbus Pharmaceuticals Holding news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
52
Balanced news tone
61 relevant articles
Price is moving more forcefully than the current news tone suggests.
86/100 classification confidence.
directly relevant articles
high-authority source matches
-6.9% over one week, +9.1% over four weeks, trend inactive, and below fair value.
Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
86/100 classification
One-week reaction
-6.9%
Price reacting lower
Trend fit
Trend inactive
9.1% over four weeks
Fair value
-47.2%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
15
Neutral
40
Negative
6
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
simplywall.st
Direct company coverage
Corbus Pharmaceuticals (CRBP) Is Down 19.6% After FDA Aligns On CRB-701 Registrational Strategy - Has The Bull Case Changed?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- simplywall.st
Seeking Alpha
Direct company coverage
Corbus Pharmaceuticals: I'd Preach Caution After Selloff On Latest Data Drop (NASDAQ:CRBP)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- Seeking Alpha
GlobeNewswire
Direct company coverage
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 11:00
- Source
- GlobeNewswire
Quiver Quantitative
Direct company coverage
Corbus Pharmaceuticals Stock (CRBP) Opinions on Updated CRB-701 Cancer Data Release
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- Quiver Quantitative
GuruFocus
Direct company coverage
Corbus Pharma (CRBP) Faces Premarket Decline Following Phase 1/2 Trial Data
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- GuruFocus
Investing.com
Direct company coverage
Corbus Pharmaceuticals stock falls on trial data release
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- Investing.com
MarketBeat
Direct company coverage
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 May 2026 07:04
- Source
- MarketBeat
GlobeNewswire
Direct company coverage
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 12:00
- Source
- GlobeNewswire
simplywall.st
Direct company coverage
We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 20 May 2026 07:00
- Source
- simplywall.st
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
GlobeNewswire
Direct company coverage
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 12:00
- Source
- GlobeNewswire
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
MT Newswires
Direct company coverage
Oppenheimer Adjusts Price Target on Corbus Pharmaceuticals to $54 From $57, Maintains Outperform Rating
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 13 May 2026 13:01
- Source
- MT Newswires
GlobeNewswire
Direct company coverage
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 May 2026 11:00
- Source
- GlobeNewswire
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
Corbus to unpack 75-patient head and neck cancer data at June 1 ASCO panel
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- Stock Titan
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value
- Tone
- Positive 66/100
- Event
- Balance sheet
- Published
- 17 Apr 2026 07:00
- Source
- Market source
Stock Titan
Direct company coverage
Two cancer trials move ahead after FDA aligns on Corbus plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Apr 2026 07:00
- Source
- Stock Titan
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Quiver Quantitative
Direct company coverage
CORBUS PHARMACEUTICALS HLDGS ($CRBP) Releases Q4 2025 Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Mar 2026 07:00
- Source
- Quiver Quantitative
Stock Titan
Direct company coverage
Corbus Pharmaceu (CRBP) Stock Price, News & Analysis
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Apr 2025 00:25
- Source
- Stock Titan
Stock Titan
Direct company coverage
Corbus Pharma's Cancer Drug CRB-701 Advances: Key Clinical Data Coming at ASCO-GU - Patient Enrollment Exceeds Targets
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 11 Feb 2025 08:00
- Source
- Stock Titan
Quiver Quantitative
Direct company coverage
Corbus Pharmaceuticals Announces Release of CRB-701 Clinical Study Abstract Ahead of ASCO GU Symposium
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Feb 2025 08:00
- Source
- Quiver Quantitative
PR Newswire
Direct company coverage
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 07 Mar 2023 08:00
- Source
- PR Newswire
PR Newswire
Direct company coverage
Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Feb 2023 08:00
- Source
- PR Newswire
The Motley Fool
Direct company coverage
Corbus Pharmaceuticals - CRBP - Stock Price & News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Sep 2021 22:15
- Source
- The Motley Fool
CNBC
Direct company coverage
'We're ahead of the pack' in the cannabinoid drug space, says CEO of synthetic drugmaker Corbus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Sep 2018 07:00
- Source
- CNBC